Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease

R. C. Dodel, Y. Du, C. Depboylu, H. Hampel, L. Frölich, A. Haag, U. Hemmeter, S. Paulsen, S. J. Teipel, S. Brettschneider, A. Spottke, C. Nölker, H. J. Möller, X. Wei, M. Farlow, N. Sommer, W. H. Oertel

Research output: Contribution to journalArticle

296 Scopus citations

Abstract

Objective: Active or passive immunisation can mitigate plaque pathology in murine models of Alzheimer's disease (AD). Recently, it has been shown that antibodies against β-amyloid (Aβ) are present in human immunoglobulin preparations (IVIgG), which specifically recognise and inhibit the neurotoxic effects of Aβ. This study reports the results from a pilot study using IVIgG in patients with AD. Methods: Five patients with AD were enrolled and received monthly IVIgG over a 6 month period. Efficacy assessment included total Aβ/Aβ1-42 measured in the CSF/serum as well as effects on cognition (ADAS-cog; CERAD) at baseline and at 6 months following IVIgG. Results: Following IVIgG, total Aβ levels in the CSF decreased by 30.1% (17.3-43.5%) compared to baseline (p<0.05). Total Aβ increased in the serum by 233% (p<0.05). No significant change was found in Aβ1-42 levels in the CSF/serum. Using ADAS-cog, an improvement of 3.7±2.9 points was detected. Scores in the MMSE were essentially unchanged (improved in four patients, stable in one patient) following IVIgG compared to baseline. Conclusion: Although the sample size of this pilot study is too small to draw a clear conclusion, the results of this pilot study provide evidence for a more detailed investigation of IVIgG for the treatment of AD.

Original languageEnglish (US)
Pages (from-to)1472-1474
Number of pages3
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume75
Issue number10
DOIs
StatePublished - Oct 1 2004

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this

    Dodel, R. C., Du, Y., Depboylu, C., Hampel, H., Frölich, L., Haag, A., Hemmeter, U., Paulsen, S., Teipel, S. J., Brettschneider, S., Spottke, A., Nölker, C., Möller, H. J., Wei, X., Farlow, M., Sommer, N., & Oertel, W. H. (2004). Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 75(10), 1472-1474. https://doi.org/10.1136/jnnp.2003.033399